thymosin alpha 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
=== Privacy of health data === Phones that can track one's whereabouts, steps and more can serve as medical devices, and medical devices have much the same effect as these phones. According to one study, people were willing to share personal data for scientific advancements, although they still expressed uncertainty about who would have access to their data. People are naturally cautious about giving out sensitive personal information. Phones add an extra level of threat. Mobile devices continue to increase in popularity each year. The addition of mobile devices serving as medical devices increases the chances for an attacker to gain unauthorized information. In 2015 the Medical Access and CHIP Reauthorization Act (MACRA) was passed, pushing towards electronic health records. In the article "Health Information Technology: Integration, Patient Empowerment, and Security", K. Marvin provided multiple different polls based on people's views on different types of technology entering the medical field most answers were responded with somewhat likely and very few completely disagreed on the technology being used in medicine. Marvin discusses the maintenance required to protect medical data and technology against cyber attacks as well as providing a proper data backup system for the information. Patient Protection and Affordable Care Act (ACA) also known as Obamacare and health information technology health care is in the digital era. Although this technology needs to be protected.
Eventually, the GLP-1 derivatives Mojsov synthesized, without her knowledge were patented as peptides able to prompt the release of insulin, but with Joel Habener as the sole-creator. Mojsov fought to have her name included in patents, with MGH eventually agreeing to amend four patents to include her name and she received her one-third of drug royalties for one year. She has continued to speak up for credit after her collaborators received various awards as new versions of GLP-1 have been approved and grown popular.
Redness of the sclera is typically caused by eye irritation causing blood vessels to expand, such as in conjunctivitis ("pink eye"). Episcleritis is a generally benign condition of the episclera causing eye redness. Scleritis is a serious inflammatory disease of the sclera causing redness of the sclera often progressing to purple. Yellowing or a light green color of the sclera is a visual symptom of jaundice. In cases of osteogenesis imperfecta, the sclera may appear to have a blue tint, more pronounced than the slight blue tint seen in children. The blue tint is caused by the showing of the underlying uveal tract (choroid and retinal pigment epithelium). In those with Ehlers–Danlos syndrome, the sclera may be tinted blue due to the lack of proper connective tissue. In very rare but severe cases of kidney failure and liver failure, the sclera may turn black. Early reports of white sclera in chimpanzees have been reported as possibly pathological and considered anomalies. Though this assumption is a good starting point in creating a foundation for what we know about sclera in animals, sources have experienced challenges acquiring large sample sizes in order to come up with conclusive evidence to support these claims fully.
Type VII was the first recessive OI type confirmed, initially found among First Nations people in Quebec. Type VIII – OI caused by a mutation in the gene LEPRE1 on chromosome 1p34.2; clinically similar to OI types II and III, depending on affected individual. Type IX – OI caused by homozygous or compound heterozygous mutation in the PPIB gene on chromosome 15q22.31. Type X – OI caused by homozygous mutation in the SERPINH1 gene on chromosome 11q13. Type XI – OI caused by mutations in FKBP10 on chromosome 17q21. The mutations cause a decrease in the secretion of trimeric procollagen molecules. Other mutations in this gene can cause autosomal recessive Bruck syndrome, which is similar to OI. Type XII – OI caused by a frameshift mutation in SP7 on chromosome 12q13.13. This mutation causes bone deformities, fractures, and delayed tooth eruption. Type XIII – OI caused by a mutation in the bone morphogenetic protein 1 (BMP1) gene on chromosome 8p21.3. This mutation causes recurrent fractures, high bone mass, and hypermobile joints. Type XIV – OI caused by mutations in the TMEM38B gene on chromosome 9q31.2. This mutation causes recurrent fractures and osteopenia, although the disease trajectory is highly variable. Type XV – OI caused by homozygous or compound heterozygous mutations in the WNT1 gene on chromosome 12q13.12. It is autosomal recessive. Type XVI – OI caused by mutations in the CREB3L1 gene on chromosome 11p11.2.
== Medical uses == Prazosin is active after taken by mouth and has a minimal effect on cardiac function due to its α1-adrenergic receptor selectivity. When prazosin is started, however, heart rate and contractility can increase in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases. The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure. Prazosin is also useful in treating urinary hesitancy associated with benign prostatic hyperplasia, blocking α1-adrenergic receptors, which control constriction of both the prostate and urethra. Although not a first-line choice for either hypertension or benign prostatic hyperplasia, it is a choice for people who present with both problems concomitantly. During its use for urinary hesitancy in military veterans in the 1990s, Murray A. Raskind and colleagues discovered that prazosin appeared to be effective in reducing nightmares. Subsequent reviews indicate prazosin is effective in improving sleep quality and treating nightmares related to post-traumatic stress disorder (PTSD). Prazosin is used off-label in the treatment of insomnia for its sedative effects. Prazosin is an inverse agonist at α1-adrenergic receptors; these receptors are expressed on dendrites that noradrenergic neurons synapse onto in the brain.
Sources: en.wikipedia.org
== Research == Flunarizine may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia, as well as being effective in rapid onset dystonia-parkinsonism (RDP). Both these conditions arise from specific mutations in the ATP1A3 gene. Flunarizine extended motor neuron survival in spinal cord, protected skeletal muscles from cell death and atrophy and extended survival by 40% in an animal model of spinal muscular atrophy. Flunarizine has also shown promise as an anti-prion medication.
There is much research currently underway looking at ways to protect the nerve (neuroprotection) or even regenerate new fibers within the optic nerve. So far there is no evidence in human studies that the so-called neuroprotectors have any beneficial effect in NAION. However, there is a new current clinical trial for the treatment of NAION in the United States with plans to include sites in India, Israel, Germany and Australia (see NORDICclinicaltrials.com and https://clinicaltrials.gov/). This trial will test the use of a synthetic siRNA that blocks caspase 2, an important enzyme in the apoptosis cycle. In addition to such research, patents have been applied for by Pfizer, The University of Southern California, Otsuka Pharmaceutical and other individual inventors for innovations related to the treatment of anterior ischemic optic neuropathy. In recent years, pentoxifylline has emerged as a potential treatment option for NAION and other diseases involving ocular ischemia. Pentoxifylline has been shown to reduce erythrocyte rigidity, resulting in decreased blood viscosity and increased flow velocity. Animal studies have demonstrated that pentoxifylline can inhibit TNF and, in turn, prevent retinal ganglion cell death and axonal degeneration associated with optic neuropathy in a dose-dependent manner.
== Function == This region functions to provide mechanical support for the articular cartilage. It serves primarily as an intermediate protective layer for tissues undergoing continuous mechanical loading. The fibril network distributes these stresses away from the chondrocyte membrane. Proteoglycan aggregates create osmotic swelling pressure that resists compression, while densely woven collagen fibrils confer tensile strength. The territorial matrix is also involved in signal transduction and nutrient exchange within the cartilage. The cartilage matrix lacks blood vessels, so nutrient and waste transport may only occur through diffusion directly through the extracellular matrix. The territorial matrix serves as a boundary layer, selectively permeable to the molecules necessary for chondrocyte. In result, the structure and composition of the territorial matrix directly influences the metabolism and function of the cells it protects. The territorial matrix also has an important role in mechanotransduction, the conversion of physical forces into biochemical signals. The mechanical movement of the territorial matrix changes ion concentrations, fluid flow, and strain on fibrils, all leading to various cellular responses like synthesis of matrix components or degradation. Mechanical stresses lead to adaptation and ultimately cartilage homeostasis; proper functioning of these signaling pathways are essential.
Southern Rhodesia would be automatically included in any British declaration of war due to its lack of diplomatic powers, but that did not stop the colonial government from attempting to demonstrate its loyalty and legislative independence through supportive parliamentary motions and gestures. The Southern Rhodesian parliament unanimously moved to support Britain in the event of war during a special sitting on 28 August 1939.
== Mechanism == Smooth muscle cells make up the involuntary muscles, which are found in most parts of the body, including the uterus, stomach and intestines, the walls of all blood vessels, and the skin. These are the areas where LMSs originate. LMSs also often develop in the retroperitoneal region which consists of the suprarenal glands, the kidney, and ureter. Just as it is not known what truly causes most sarcomas, LMSs have similarly complex karyotypes and it is suggested that because of the complexity, genomic instability might be the cause. Uterine leiomyosarcomas come from the smooth muscle in the muscle layer of the uterus. Cutaneous leiomyosarcomas derive from the pilo-erector muscles in the skin. Gastrointestinal leiomyosarcomas might come from smooth muscle in the gastrointestinal (GI) tract, or alternatively, from a blood vessel. At most other primary sites—retroperitoneal extremity (in the abdomen, behind the intestines), truncal, abdominal organs, etc.—leiomyosarcomas appear to grow from the muscle layer of a blood vessel (the tunica media). Thus, a leiomyosarcoma can have a primary site of origin anywhere in the body from a blood vessel. The tumors are usually hemorrhagic, soft, and microscopically marked by pleomorphism, abundant (15–30 per 10 high-power fields) abnormal mitotic figures, and coagulative tumor cell necrosis. The differential diagnosis, which includes spindle cell carcinoma, spindle cell melanoma, fibrosarcoma, malignant peripheral nerve sheath tumor, and even biphenotypic sinonasal sarcoma, is wide.
Sources: en.wikipedia.org
=== Gag order === Syngenta sued to stop communication by Swiss health authorities with the Swiss public regarding the "relevance" of specific metabolites of chlorothalonil that Swiss authorities detected in high concentrations in the groundwater from which hundreds of thousands of Swiss people obtain drinking water. The court banned Swiss health authorities from communicating with the public about the dangers posed by some of the metabolites.
12 September 1946 the minister for external affairs in India, Jawaharlal Nehru demanded in a letter to the Commander in Chief and Defence Secretary, that a large-scale reform should be implemented to improve the Indian Army. Calcutta had been ravaged by large communal riots, but the British Indian Army was able to restore order. Nehru demanded with urgency, that the Indian Army should safeguard India's new democracy. Nehru was a nationalist and opposed India's "divide and rule" policy.
=== Developmental plasticity === Biotic and abiotic factors experienced during development will affect developmental resource allocation leading to phenotypic variation, also referred to as developmental plasticity. As in all insects, environmental factors can influence several aspects of development in Drosophila melanogaster. Fruit flies reared under a hypoxia treatment experience decreased thorax length, while hyperoxia produces smaller flight muscles, suggesting negative developmental effects of extreme oxygen levels. Circadian rhythms are also subject to developmental plasticity. Light conditions during development affect daily activity patterns in Drosophila melanogaster, where flies raised under constant dark or light are less active as adults than those raised under a 12-hour light/dark cycle. Temperature is one of the most pervasive factors influencing arthropod development. In Drosophila melanogaster temperature-induced developmental plasticity can be beneficial and/or detrimental. Most often lower developmental temperatures reduce growth rates which influence many other physiological factors. For example, development at 25 °C increases walking speed, thermal performance breadth, and territorial success, while development at 18 °C increases body mass, wing size, all of which are tied to fitness. Moreover, developing at certain low temperatures produces proportionally large wings which improve flight and reproductive performance at similarly low temperatures (See acclimation).
=== Sneath's index === Sneath's index takes into account 134 categories of activity and structure. Dissimilarity index D is a percentage value of the sum of all properties not shared between two replaced amino acids. It is percentage value expressed by
== Applications == Perhaps ion mobility spectrometry's greatest strength is the speed at which separations occur—typically on the order of tens of milliseconds. This feature combined with its ease of use, relatively high sensitivity, and highly compact design have allowed IMS as a commercial product to be used as a routine tool for the field detection of explosives, drugs, and chemical weapons. Major manufacturers of IMS screening devices used in airports are Morpho and Smiths Detection. Smiths purchased Morpho Detection in 2017 and subsequently had to legally divest ownership of the Trace side of the business (Smiths have Trace Products) which was sold on to Rapiscan Systems in mid 2017. The products are listed under ETD Itemisers. The latest model is a non-radiation 4DX. In the pharmaceutical industry, IMS is used in cleaning validations, demonstrating that reaction vessels are sufficiently clean to proceed with the next batch of pharmaceutical product. IMS is much faster and more accurate than HPLC and total organic carbon methods previously used. IMS is also used for analyzing the composition of drugs produced, thereby finding a place in quality assurance and control. As a research tool, ion mobility is becoming a more widely used technique for the analysis of biological materials, specifically proteomics, metabolomics and glycomics. For example, in proteomics IMS-MS using matrix-assisted laser desorption/ionization (MALDI) as the ionization method has helped by providing faster high-resolution separations of protein pieces in analysis.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.